Abstract: A system and method for efficient thermoelectric power generation by combining natural gas as a thermal source with emitters, such as Silicon Carbide, highly-doped Silicon Carbide semiconductor material as cells, harvesting of electric power through in situ formation of Graphene Carbon, and semiconductor materials. The system is can yield orders of magnitude greater power efficiency over thermoelectric power generation units used in space travel, by practicing the invention, natural gas, such as the 288.7 billion cubic currently wasted by the environmental damaging practice of flaring off, can be converted into useful electricity for transport over low-cost transmission line infrastructure rather than possible future high-cost pipelines. Also, by practicing the invention, households can be provided with standby power, power during natural disasters, such as hurricanes, by converting available natural or propane gas rather relying on generators with single digit efficiency.

Abstract: A system for converting solar energy to electric power and a glass for a layer of solar cells in the system. A solar panel installation comprises a solar panel with at least one solar cell formed with a stack of plural layers of photovoltaic wafer material. Each layer of wafer material has an edge direction from a recipient edge to a back edge, and the solar cell is retained within the solar panel installation with the photovoltaic wafer material disposed with the edge direction aligned with incident solar direction. Reflective material applied to facing surfaces of the photovoltaic wafer material facilitates internal reflection of photons. A glass layer has plural sheets of Graphene layered to form a Graphene Cube constructed to exhibit Multiple Excitation Generation (MEG). A method for assembling the glass fixes a top glass above a bottom glass with photovoltaic wafer material establishing a fixed distance therebetween.

Abstract: The present invention is directed towards classifying tumor biomarkers, particularly membrane receptors, and more particularly the gastrin-releasing peptide (GPR) receptors, identified in patient samples, then linking therapeutic agents (chemical, radiological, or biological) to patient-specific ligands that bind to such receptors, clinicians can produce diagnostic and treatment compositions and implement treatment regimens which, by using the classified and identified biomarkers, and due to their improved accuracy, increase success and decrease undesired side effects from such treatments.